This supporting material document contains detailed descriptions of the two cytosolic phospholipase A 2 α (cPLA 2 α) assays and all compounds (32 -42), which were selected and acquired for the evaluation of the effect of these compounds on the activity of cPLA 2 α (except the most active compound 31). Compound 31 that showed marked activity in the cPLA 2 α cellfree assay is described in the main document; figures presenting concentrations response curves of 31 as well as of the cPLA 2 α reference inhibitor 43 are presented in this supporting material.
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Methods

Determination of cell-free activity of isolated human recombinant cPLA 2 α
The cPLA 2 α coding sequence was cloned from pVL1393 plasmid (kindly provided by Dr. Wonhwa Cho, University of Illinois at Chicago) into pFastBac TM HT A containing a 6  his-tag coding sequence. The recombinant plasmid was transformed into DH10Bac TM E. coli. Sf9 cells were transfected with recombinant bacmid DNA using Cellfectin® Reagent and the generated baculovirus was amplified. Overexpression of His-tagged cPLA 2 in baculovirus-infected Sf9 cells and isolation using Ni-NTA agarose beads was performed as described (de Carvalho et al., 1993) . Multilamelar vesicles (MLVs) were prepared by drying 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (PAPC) and 1-palmitoyl-2-oleoyl-sn-glycerol (POG) in a ratio of 2:1 (nn -1 , in chloroform) under nitrogen in glass vials. After addition of 20 mM Tris buffer (pH 7.4) containing 134 mM NaCl and 1 mg/ml fatty acid free BSA, the MLV suspension was disrupted by several freeze-thaw cycles (liquid nitrogen) and then extruded 11 times with a mini-extruder (Avanti Polar Lipids, Inc.) through a polycarbonate membrane (100 nm pore diameter) at room temperature (above transition temperature of the lipids) to produce LUV (large unilamelar vesicles). Final total concentration of lipids was 250 µM in 200 µl. Test compounds and 1 mM Ca 2+ were added to the vesicles, and the reaction was started by addition of 500 ng his-tagged cPLA 2 (in 10 µl buffer). After 1 h at 37 °C, 1.6 ml MeOH was added, and AA was extracted by RP-18 solid phase extraction. Following derivatisation with p-anisidinium chloride, the resulting derivate was analyzed by RP-HPLC at 249 nm as described (Knospe et al., 1988) .
Determination of cPLA 2 α activity in a cell-based model using human peripheral blood monocytes
Fresh blood was collected in heparinized tubes (16 I.E. heparin/ml blood) by venipuncture from fasted (12 h) adult male and female healthy volunteers, with consent (Blood Center, University Hospital, Tuebingen, Germany). The subjects had no apparent inflammatory conditions and had not taken oral contraceptives (or other sex hormones) or anti-inflammatory drugs for at least ten days prior to blood collection. The blood was subjected to centrifugation at 4,000  g/20 min/20 °C and peripheral blood mononuclear cells were promptly isolated by dextran sedimentation and centrifugation on Nycoprep cushions (PAA Laboratories, Linz, Austria). Cells were collected, washed three times with cold PBS and then monocytes were separated by adherence for 1 h at 37 °C to culture flasks (Greiner, Nuertingen, Germany; cell density was 20  10 6 cells/ml of RPMI 1640 medium containing 2 mM L-glutamine and 50 µg/ml penicillin/streptomycin), which gave a purity of >85%, defined by forward-and side-light scatter properties and detection of the CD14 surface molecule by flow cytometry (BD FACS Calibur). Monocytes were finally resuspended in ice-cold PBS plus 1 mg/ml glucose (PG buffer) or in PG buffer supplemented with 1 mM CaCl 2 (PGC buffer).
Monocytes (2 × 10 6 /ml RPMI) were incubated with 5 nM [ 3 H]-arachidonic acid for 2 h at 37 °C and 6% CO 2 . Cells were washed twice with PBS buffer containing 1 mg/ml glucose and 2 mg/ml BSA, resuspended in PBS buffer containing 1 mg/ml glucose (5 × 10 6 /ml), supplemented with 1 mM CaCl 2 , pre-incubated with the test compounds for 15 min at 37 °C, and stimulated with 1 µM Ca 2+ -ionophore A23187 for 5 min at 37 °C. The samples were stopped on ice for 10 min and centrifuged at 1200 × g, 10 min. Aliquots of the supernatants were mixed with 2 ml Ultima GoldTM XR and measured on a scintillation counter (Micro Beta Trilux, Perkin Elmer, Waltham, MA, USA) to detect released [ 3 H]-arachidonic acid. 
